CeriBell Corp (CBLL) - Market Cap to Earnings
The share price history of CeriBell, Inc. (CBLL) helps assess the effectiveness of the SaaS model for AI EEG monitors, which ensures a stable cash flow and high profitability. The current figure is -14.70. Positive momentum is supported by the planned expansion of portable system production and the modernization of workshops. However, export restrictions and semiconductor shortages are hindering the brand's expansion into new markets and slowing down service maintenance.
Comprehensive metric breakdowns and analytics for CeriBell Corp (CBLL)
- stock value and consensus price forecast:
- market capitalization indicators:
- book value of equity indicators:
- company liabilities and liquidity data:
- earnings and valuation multiples indicators:
CBLL - Net Profit|Company Profit Forecast CeriBell, Inc.|CBLL - Price to Earnings Ratio|Price to Future Earnings Ratio CeriBell Inc|CBLL - PEG Multiple|Enterprise Value to EBITDA Ratio CeriBell, Inc.|CBLL - Operating profit before deduction of amortization|Net earnings per share for the last four quarters CeriBell|CBLL - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months ceribell.com|CBLL - Earnings growth in current year|Net earnings per share growth forecast for next year CeriBell, Inc.
Comprehensive company analysis:ceribell.com
CeriBell, Inc. (CBLL) investments in human capital to expand EEG systems directly impact net income, forming the denominator of this ratio. The metric correlates current market capitalization with annual earnings, determining the cost of one dollar of profit and the business's level of maturity. The stability of this ratio confirms the asset's defensive qualities, filtering out speculative noise. P/E valuation analysis allows for the determination of the actual return on R&D investments.
Analysis of competing companies
Price to Earnings Ratio biogen.com (BIIB)|P/E Multiple NBIX|RGC - Market Cap to Earnings|Price to Earnings Ratio Axsome Therapeutics Inc AXSM|Company Value to Net Income ACAD|Xenon Pharmaceuticals - P/E Multiple|Business Payback Period vikingtherapeutics.com VKTX|SUPN: P/E Multiple|CPRX (Catalyst Pharma) - Price to Earnings Ratio|DNLI (Denali Therapeutics Inc) - P/E Multiple|Market Cap to Earnings Harmony Corp HRMY|Price to Earnings Ratio Biohaven Ltd. (BHVN)|Price to Earnings Ratio AMLX (amylyx.com)|Price to Earnings Ratio Trevi Therapeutics, Inc. TRVI|Praxis Precision Medicines Inc - Price to Earnings Ratio|AVXL: Price to Earnings Ratio|Company Value to Net Income PRTA (Prothena Corporation)|ALEC: P/E Multiple|ANNX - Business Payback Period|Price to Earnings Ratio Omeros Corp|Price to Earnings Multiple NGNE (Neurogene Inc)|P/E Multiple ACIU|Price to Earnings Ratio Voyager Corp VYGR|Neumora Therapeutics - Price to Earnings Ratio|Business Payback Period scilexholding.com (SCLX)|Tevogen Bio - P/E Multiple|Alpha Cognition (ACOG) - Price to Earnings Ratio|CGTX: P/E Multiple|IKT (Inhibikase Pharma) - Price to Earnings Ratio|Price to Earnings Ratio Cassava Sciences, Inc.|Price to Earnings Ratio ASRT|Price to Earnings Ratio Coya Therapeutics, Inc. (COYA)|Price to Earnings Ratio VTGN (vistagen.com)|Price to Earnings Ratio Ovid Therapeutics OVID|ABOS: Price to Earnings Multiple|CervoMed Inc. - P/E Multiple|Market Cap to Earnings Alterity Therapeutics|CLNN (clene.com) - Price to Earnings Ratio|PepGen (PEPG) - P/E Multiple|Price to Earnings Ratio Jupiter Neurosciences|RLMD: Company Value to Net Income|Price to Earnings Ratio Annovis Bio, Inc. (ANVS)|GRCE - Market Cap to Earnings|P/E Multiple AIFF (Firefly Neuroscience)|KLTO - Price to Earnings Ratio|NeuroSense Therapeutics, Ltd. - P/E Multiple|Market Cap to Earnings Reviva Pharmaceuticals, Inc.|metaviatx.com (MTVA) - Price to Earnings Ratio|neuraxis.com - Company Value to Net Income|HSDT (Helius Medical Technologies, Inc.) - P/E Multiple|Passage Bio Corp (PASG) - Business Payback Period|P/E Multiple NEUP|Price to Earnings Ratio NERV (Minerva)|P/E Multiple ATHA (Athira Pharma, Inc.)|addextherapeutics.com (ADXN) - Market Cap to Earnings|ALZN - Price to Earnings Ratio|CYCN: Price to Earnings Ratio|protagenic.com (PTIX) - Price to Earnings Ratio|KTTA (Pasithea Therapeutics Corp.) - Price to Earnings Ratio|Price to Earnings Ratio CRGT|ATXI: Company Value to Net Income|P/E Multiple BCLI|Business Payback Period Cara Therapeutics Inc.|Price to Earnings Ratio Chromocell Therapeutics Corporation CHRO|ELYM: Price to Earnings Multiple|Intra-Cellular - P/E Multiple|longboardpharma.com (LBPH) - Price to Earnings Ratio|MRNS (Marinus Pharmaceuticals, Inc.) - Price to Earnings Ratio|NKGN - Business Payback Period|NRBO (NeuroBo) - P/E Multiple|Price to Earnings Ratio Sage Therapeutics Inc (SAGE)|P/E Multiple SNPX|Price to Earnings Ratio TRVN (trevena.com)|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|anewmeds.com - Price to Earnings Ratio|CERE - Price to Earnings Ratio
